Chimeric antigen receptor T cells and checkpoint inhibitors might represent promising immunotherapeutics for AML.37 Oncolytic virus immunotherapy has also become a potential strategy for treating AML.38–40 Shen et al.41 reported that combining an oncolytic VSV encoding IFNβ with PD-L1 blockade enhanced the therapeutic outcomes of the treatment of murine AML. This evidence concerns the gene CD274 and acute myeloid leukemia.